Status:
ACTIVE_NOT_RECRUITING
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer
Lead Sponsor:
Regina Elena Cancer Institute
Collaborating Sponsors:
Azienda Sanitaria Locale n. 2 - Lanciano Vasto Chieti
Campus Bio-Medico University
Conditions:
DNA Damage
Gastric Cancer
Eligibility:
All Genders
18+ years
Brief Summary
We envisioned a scenario where the interaction between the ATM-Chk2/ATR-Chk1 pathways and Hippo enables GC cells to overcome chemotherapy-induced death stimuli. First, ATM-Chk2 and ATR-Chk1 were found...
Detailed Description
This prospective, multicenter, non-interventional trial is designed for prospectively validating the DDR-Hippo signature as a predictor of inferior PFS in patients with inoperable locally advanced or ...
Eligibility Criteria
Inclusion
- Age \>18 years;
- Histologic diagnosis of locally advanced or metastatic gastric carcinoma (GC) or gastroesophageal junction carcinoma (EJC);
- Biological material adequate for molecular analysis to be performed, taken (at surgery or by biopsy) prior to the administration of any anti-tumor treatment (chemotherapy and/or radiotherapy);
- ECOG PS 0-2;
- Adequate hematologic, hepatic, and renal function;
- Measurable disease according to RECIST criteria;
- Written informed consent.
Exclusion
- Previous chemotherapy for metastatic disease;
- Comorbidities not controlled with appropriate medical therapy;
- Brain metastasis;
- Patient unable to give adequate consent for the study
Key Trial Info
Start Date :
October 26 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2024
Estimated Enrollment :
167 Patients enrolled
Trial Details
Trial ID
NCT06204523
Start Date
October 26 2018
End Date
August 30 2024
Last Update
January 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
"Regina Elena" National Cancer Institute
Rome, Italy, 00144